Top Pharmaceutical Companies in Dublin (44)
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. We are navigating the complexities of healthcare and providing scaled...
Cardinal Health's Top Stability & Growth Strengths
Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.
Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.
Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we...
Regeneron's Top Stability & Growth Strengths
Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.
Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.
Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business...
With a 170-year heritage, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. We have approximately 9 100 employees at 69 established offices in over 50 countries and we improve the health of patients in more than 150 countries through our high quality, affordable medicines. Aspen focuses on marketing and manufacturing...
Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span...
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical...
Parexel's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Parexel is consistently viewed as a top-tier, full-service CRO, reinforced by repeated industry awards and strong site collaboration recognition. These signals indicate competitive strength in winning and delivering complex global programs.
Strategic Partnerships: Feedback suggests multi-year collaborations to embed advanced analytics and AI (e.g., Palantir and other AI initiatives) are intended to improve trial efficiency and differentiation. Such partnerships underscore continued investment in modernization and execution.
Market Expansion: Feedback suggests the company opened a new global headquarters in Raleigh and continues to reference a 20,000+ to 24,000+ global workforce, indicating operational scaling. Physical expansion and ongoing hiring activity support broader delivery capacity across regions.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and developing meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. Our...
Axios International is a leading healthcare access company that has worked since 1997 to transform access to healthcare by putting quality care and treatment within reach. With over 28 years of experience, they design and implement effective and sustainable solutions to patient access challenges in emerging markets, serving nearly 10 million people across more than 100 countries to ensure all...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market position is reinforced by being the largest pharmaceutical company in Asia, a consistent top‑15–20 global player by revenue, and operations across roughly 80 countries.
Innovation-Driven Growth: Innovation momentum is evident through a first‑in‑class FDA‑approved narcolepsy treatment and positive late‑stage results for oveporexton and zasocitinib. Multiple priority reviews and planned launches further support the pipeline.
Profitability: Profitability is strengthening with a sharp increase in net profit and a significant rise in operating profit, accompanied by an upgraded full‑year outlook. Cost discipline and transformation initiatives are also helping protect earnings while investment rises.
Applegreen is a leading international roadside retailer operating in the Republic of Ireland, the United Kingdom, and the United States. The company manages a vast network of motorway service areas, travel plazas, and petrol stations, offering premium food and beverage options through its own brand and partnerships with recognized global food brands, alongside comprehensive convenience store services.
Applegreen's Top Stability & Growth Strengths
Market Expansion: Expansion across the United States, Ireland, and the United Kingdom is underpinned by a multi-year, €1 billion program, including major projects in Massachusetts, New Jersey, New York, and Colorado and acquisitions like Cornwall Services. The footprint now spans close to 600 locations with new service areas and travel plazas coming online across core corridors.
Future-Ready Strategy: EV infrastructure is scaling rapidly, with Applegreen Electric surpassing 1,500 charging ports across multiple U.S. states alongside Ireland and the UK. Sites are being modernized into broader energy and hospitality hubs through ultra-fast charging and expanded food and retail offerings.
Strong Market Position & Advantage: Applegreen is a leading motorway service-area operator—number one in Ireland and the United States and second in the United Kingdom. Positions along regulated, hard-to-replicate corridors and long-term concessions create barriers to entry that reinforce its competitive standing.
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments...
BioMarin Pharmaceutical Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Results show double‑digit revenue growth in 2025, with acceleration in Q4 driven by Voxzogo uptake and steady enzyme therapies across 55 markets. 2026 guidance points to a higher revenue range, indicating continued expansion.
Profitability: Disclosures highlight strong profitability with $828 million in 2025 operating cash flow and a targeted ~40% non‑GAAP operating margin for 2026 (excluding Amicus). Non‑GAAP EPS guidance of $4.95–$5.15 further signals operating leverage.
Diversified Revenue Streams: The portfolio spans multiple enzyme therapies and the achondroplasia franchise, and the pending Amicus acquisition would add Galafold and Pombiliti + Opfolda to diversify revenues from mid‑2026 onward. Enzyme therapies collectively grew in 2025, supporting breadth beyond a single asset.
Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease. We are inspired by some...
Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one...
PTC is a patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for patients with rare and serious disease
Peninsula is a global leader in marine energy solutions and fuel bunkering, operating as a physical distributor and reseller of global marine fuel. They offer conventional and lower carbon fuel solutions, including biofuels and LNG, across over 500 ports worldwide.
At Astellas, we strive to be a cutting-edge, value-driven life science innovator. This means working at the forefront of healthcare change to turn innovative science into the best outcomes for patients. Operating in approximately 70 countries with more than 14,000 employees, we are relentless in our pursuit of scientific progress and in tackling unmet medical needs. Visit our Global Astellas...
Astellas Pharma's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record level in FY2024 with double‑digit year‑over‑year growth, and management raised FY2025 guidance after continued momentum through the first nine months. Company updates attribute this to strong contributions from “Strategic Brands” including PADCEV, VYLOY, VEOZAH, IZERVAY and sustained XTANDI demand.
Profitability: Core operating profit increased markedly faster than sales in FY2025 year‑to‑date, reflecting margin expansion. Management links improvement to mix benefits from strategic brands and cost programs such as the Sustainable Margin Transformation initiative.
Strong Market Position & Advantage: Astellas demonstrates category leadership in niches—XTANDI in prostate cancer and PADCEV + Keytruda setting a new first‑line standard in advanced urothelial cancer with later perioperative expansion. First‑in‑class positions in CLDN18.2 gastric cancer (VYLOY) and non‑hormonal menopause therapy (VEOZAH) further strengthen its competitive footing.
SCOPE is a Healthcare & Pharmaceuticals company with locations in Ireland, UK and USA that is dedicated to providing Healthcare Professionals & patients with high quality, effective and innovative products. Our family has been working within the healthcare sector in Ireland & UK for over 80 years. With this heritage Scope was founded by John and Tom Freyne in 2009. What...
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Listening for needs and delivering solutions. As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal...
